| ★ 31.10.2026 17:28 UTC | Looking For Growth, Income, and Stability? This Stock Could Offer All 3 | Motley Fool |
| ★ 31.10.2026 07:10 UTC | Amgen (AMGN) Gets A Fresh Look As Phase 3 Wins Meet A Pricey Narrative | Simply Wall St. |
| ★ 31.10.2026 07:08 UTC | New CFO Appointment Could Be A Big Moment For Mattel (MAT) ◆ Leadership change | Simply Wall St. |
| ★ 30.10.2026 12:41 UTC | How to Build $6,800 a Month in Dividend Income Without Selling a Single Share | 24/7 Wall St. |
| ★ 29.10.2026 18:41 UTC | Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians | TIKR |
| ★ 29.10.2026 12:15 UTC | Amgen (AMGN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates | Zacks |
| ★ 29.10.2026 09:32 UTC | Amgen Braces for Rising Expenses Ahead of Q3 Results—Is a Profit Squeeze Looming? | 24/7 Wall St. |
| ★ 28.10.2026 20:30 UTC | AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS | PR Newswire |
| ★ 28.10.2026 19:13 UTC | What Could Amgen (AMGN) Rare Disease Updates Mean For Its Growth Story? | Simply Wall St. |
| ★ 28.10.2026 13:00 UTC | Foghorn Therapeutics Inc. (FHTX) Expected to Beat Earnings Estimates: Should You Buy? ▲ Earnings beat | Zacks |
| ★ 27.10.2026 22:27 UTC | AMGEN ANNOUNCES 2026 FOURTH QUARTER DIVIDEND | PR Newswire |
| ★ 27.10.2026 20:00 UTC | AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026 | PR Newswire |
| ★ 27.10.2026 19:45 UTC | Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue | Motley Fool |
| 31.10.2026 12:41 UTC | Dow Jones Futures: Stock Market Sells Off As Apple, Palantir, Midterm Elections Loom; What To Do | Investor's Business Daily |
| 30.10.2026 22:51 UTC | Big Homes, Big Loans | Barrons.com |
| 30.10.2026 15:34 UTC | Stocks Fall Sharply on Intel and Amazon Sell-offs and Crypto Heist | Barchart |
| 30.10.2026 14:45 UTC | Regeneron Soars 12% on Dupixent-Fueled Q3 Beat: “One of Our Strongest Years Ever” | TIKR |
| 30.10.2026 14:21 UTC | AstraZeneca Has an $80 Billion Dream and a Plan to Fix Its Stalling Stock | Barrons.com |
| 30.10.2026 13:21 UTC | AZN Q3 Earnings Beat Estimates, Oncology Drugs Drive Sales Growth ▲ Earnings beat | Zacks |
| 30.10.2026 11:15 UTC | What Sent Eli Lilly Stock Higher? | Trefis |
| 30.10.2026 11:05 UTC | What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Oct. 28 | GuruFocus.com |
| 29.10.2026 20:50 UTC | Amgen (AMGN) Increases Despite Market Slip: Here's What You Need to Know | Zacks |
| 29.10.2026 11:53 UTC | Caterpillar Revenue Miss, Outlook Dig Hole For Dow Jones Industrial Average | Investor's Business Daily |
| 29.10.2026 11:04 UTC | What SPDR Dow Jones Industrial Avg ETF (DIA) Sold: Goldman Leads on Oct. 27 | GuruFocus.com |
| 28.10.2026 14:20 UTC | Amgen Q3 Earnings: Will Strong Drug Sales Offset Headwinds? | Zacks |
| 28.10.2026 11:05 UTC | What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Monday | GuruFocus.com |
| 28.10.2026 11:04 UTC | State Street SPDR Dow Jones (DIA) Buys $15.9 Million More Goldman Sachs on Oct. 26 | GuruFocus.com |
| 28.10.2026 09:25 UTC | If Eli Lilly Stock Looks Expensive, You Need To Read This | Trefis |
| 27.10.2026 17:47 UTC | Dow Jones Biotech Giant Amgen Breaks Out Ahead Of Q3 Earnings Results | Investor's Business Daily |
| 27.10.2026 16:44 UTC | Has Regeneron Stock Become A Different Bet? | Trefis |